Health Replimune Resubmits Melanoma Drug After FDA Leadership Exodus May 29, 2026 Third Submission Follows Major Regulatory Changes Replimune Group will resubmit its biologics license application for melanoma therapy RP1 in the coming days. Replimune made the decision after significant leadership changes…